Skip to Content
Merck
  • Nox2 signaling and muscle fiber remodeling are attenuated by losartan administration during skeletal muscle unloading.

Nox2 signaling and muscle fiber remodeling are attenuated by losartan administration during skeletal muscle unloading.

Physiological reports (2021-01-06)
Jeffrey M Hord, Marcela M Garcia, Katherine R Farris, Vinicius Guzzoni, Yang Lee, Matthew S Lawler, John M Lawler
ABSTRACT

Reduced mechanical loading results in atrophy of skeletal muscle fibers. Increased reactive oxygen species (ROS) are causal in sarcolemmal dislocation of nNOS and FoxO3a activation. The Nox2 isoform of NADPH oxidase and mitochondria release ROS during disuse in skeletal muscle. Activation of the angiotensin II type 1 receptor (AT1R) can elicit Nox2 complex formation. The AT1R blocker losartan was used to test the hypothesis that AT1R activation drives Nox2 assembly, nNOS dislocation, FoxO3a activation, and thus alterations in morphology in the unloaded rat soleus. Male Fischer 344 rats were divided into four groups: ambulatory control (CON), ambulatory + losartan (40 mg kg-1  day-1 ) (CONL), 7 days of tail-traction hindlimb unloading (HU), and HU + losartan (HUL). Losartan attenuated unloading-induced loss of muscle fiber cross-sectional area (CSA) and fiber-type shift. Losartan mitigated unloading-induced elevation of ROS levels and upregulation of Nox2. Furthermore, AT1R blockade abrogated nNOS dislocation away from the sarcolemma and elevation of nuclear FoxO3a. We conclude that AT1R blockade attenuates disuse remodeling by inhibiting Nox2, thereby lessening nNOS dislocation and activation of FoxO3a.

MATERIALS
Product Number
Brand
Product Description

Sigma-Aldrich
Diphenyleneiodonium chloride, ≥98%
Sigma-Aldrich
Anti-Na+/K+ ATPase α-1 Antibody, clone C464.6, clone C464.6, Upstate®, from mouse
Sigma-Aldrich
Anti-FOXO3 antibody produced in rabbit, affinity isolated antibody, buffered aqueous solution